Form 4: Elevation Oncology Director Reports Option Dispositions Following Concentra Biosciences Merger Completion

Elevation Oncology, Inc. Director Alan B. Sandler reported the disposition of stock options as the company completed its merger with Concentra Biosciences, LLC, involving a tender offer of $0.36 cash per share plus a contingent value right.

Summary

• Elevation Oncology, Inc. (ELEV) completed its merger with Concentra Biosciences, LLC and its subsidiary Concentra Merger Sub VI, Inc. on July 23, 2025.
• The merger followed a tender offer for all outstanding shares of Elevation Oncology common stock at an offer price of $0.36 per share in cash, plus one non-transferable contractual contingent value right (CVR) per share.
• Immediately prior to the merger's effective time, all outstanding stock options became fully vested and exercisable.
• Unexercised options were cancelled and converted into a cash amount equal to the product of (1) the excess of the $0.36 cash amount over the option's exercise price and (2) the number of shares underlying the option, plus one CVR per underlying share.
• Options with an exercise price equal to or greater than the $0.36 cash amount were cancelled for no consideration.
• Director Alan B. Sandler disposed of 55,000 stock options with an exercise price of $4.41, 35,000 stock options with an exercise price of $3.35, and 35,000 stock options with an exercise price of $0.3051, all on July 23, 2025, pursuant to the merger terms.
• The 55,000 and 35,000 options with exercise prices of $4.41 and $3.35 respectively were cancelled for no consideration as their exercise prices exceeded the $0.36 cash offer.
• The 35,000 options with an exercise price of $0.3051 would have yielded cash of $1,921.50 (($0.36 $0.3051) * 35,000) and 35,000 CVRs.

Sentiment

Score: 6

Explanation: The filing is a factual report of a completed merger and insider transaction. While some options were cancelled for no consideration, the overall merger completion provides a definitive outcome for shareholders, including a cash component and potential future value via CVRs, which is generally an expected resolution for an announced acquisition.

Positives

• The completion of the merger provides a defined cash payout and potential future value via CVRs for Elevation Oncology shareholders.
• Stock options with an exercise price below the cash offer price received cash consideration and CVRs, providing value to those option holders.

Negatives

• Stock options with exercise prices equal to or greater than the $0.36 cash offer price were cancelled for no consideration, resulting in a loss of value for those specific option holders, including a significant portion of the director's holdings.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on the achievement of specific future milestones, which may or may not occur.
• The company is now a wholly-owned subsidiary, meaning its independent operational and financial risks are absorbed by the parent company, Concentra Biosciences.

Future Outlook

The future outlook for Elevation Oncology as an independent entity is limited as it is now a wholly-owned subsidiary of Concentra Biosciences. Future value for former shareholders is tied to the contingent value rights, which depend on the achievement of specific, undisclosed milestones.

Industry Context

This transaction represents a common strategy in the biotechnology and pharmaceutical sectors where larger entities acquire smaller companies, often with promising but early-stage assets, to expand their pipelines. The use of Contingent Value Rights (CVRs) is a frequent mechanism in such deals to bridge valuation gaps and share future risks and rewards related to clinical or regulatory milestones.

Comparison to Industry Standards

• The 'cash plus CVR' deal structure is a common approach in biotech M&A, particularly for companies with clinical-stage assets where future value is contingent on development milestones. This structure aligns the interests of the acquirer and the target's former shareholders regarding the future success of the acquired assets.
• The cancellation of out-of-the-money options is standard practice in mergers where the offer price is below the option's strike price, reflecting that these options held no intrinsic value at the time of the acquisition.

Corporate Governance

Related Party Transactions

• The disposition of stock options by Director Alan B. Sandler occurred pursuant to the terms of the Merger Agreement, which is a transaction between the company and its acquirer, impacting company insiders.

Stakeholder Impact

• Shareholders received a cash payment of $0.36 per share and one CVR per share, providing liquidity and potential future value.
• Option holders were impacted based on their option's exercise price relative to the $0.36 cash offer, with some receiving cash and CVRs, and others receiving no consideration.

Next Steps

• The realization of value from the Contingent Value Rights (CVRs) will depend on the achievement of specific milestones as outlined in the CVR Agreement.

Key Dates

Keywords

SEC Form 4, Merger, Acquisition, Tender Offer, Stock Options, Contingent Value Rights, Insider Transaction, Elevation Oncology, Concentra Biosciences, Corporate Governance